There is reason for the enthusiasm behind Elevation’s anti-Claudin18.2 antibody-drug conjugate, but no such good news for Zai Lab’s zolbetuximab challenger.

Private Company Edition: Former Merck R&D head Roger Perlmutter and his new team have accessed drug candidates in oncology and neurodegenerative diseases from three companies, along with new funding. Also, Carmot raised $150m in series E equity and BenchSci brought in $70m.

An increasing number of biotech companies originating from the US and Asia are building EU headquarters in Switzerland. Scrip spoke with four key opinion leaders on the motivations behind these decisions and the role the domestic ecosystem has to play, from school systems to neutral politics and beyond.

Tracing its roots back to Basel in the late nineteenth century, Sandoz has confirmed the location of its new planned permanent headquarters post-spin.